{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:30:58Z","timestamp":1768818658664,"version":"3.49.0"},"reference-count":55,"publisher":"SAGE Publications","issue":"2_suppl","license":[{"start":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T00:00:00Z","timestamp":1469491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Although there is still no cure for multiple sclerosis (MS), the introduction of several innovative drugs with modes of action different from that of the existing drug arsenal and the progress in monitoring disease progression by imaging and using biomarkers are currently causing a knowledge surge. This provides opportunities for improving patient disease management. New therapies are also under development and pose challenges to the regulatory bodies regarding the optimal design of clinical trials with more patient-focused clinical endpoints. Moreover, with the upcoming patent expiry of some of the key first-line MS treatments in Europe, regulatory bodies will also face the challenge of recommending marketing authorisation for generic and abridged versions based on appropriate requirements for demonstrating equality\/similarity to the innovator\u2019s product. <\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p> The goal of this article is to improve the understanding of the relevant guidance documents of the European Medicines Agency (EMA) on clinical investigation of medicinal products and to highlight the issues that the agency will need to clarify regarding follow-on products of first-line MS treatments. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> Today, it is clear that close collaboration between patients, healthcare professionals, regulatory bodies and industry is crucial for developing new safe and effective drugs, which satisfy the needs of MS patients. <\/jats:p><\/jats:sec>","DOI":"10.1177\/1352458516650744","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T11:39:53Z","timestamp":1469619593000},"page":"47-59","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["The regulator\u2019s perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?"],"prefix":"10.1177","volume":"22","author":[{"given":"Daan JA","family":"Crommelin","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Sciences, Utrecht University, Utrecht, The Netherlands"}]},{"given":"Karl","family":"Broich","sequence":"additional","affiliation":[{"name":"President and Head of the Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM), Bonn, Germany"}]},{"given":"Chris","family":"Holloway","sequence":"additional","affiliation":[{"name":"European Regulatory Consultant, Chief Scientific Officer of ERA Consulting GmbH, Walsrode, Germany"}]},{"given":"Bianca","family":"Meesen","sequence":"additional","affiliation":[{"name":"Managing Director at Ismar Healthcare, Lier, Belgium"}]},{"given":"Jana","family":"Lizrova Preiningerova","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University, Prague, Czech Republic"}]},{"given":"Jean-Louis","family":"Prugnaud","sequence":"additional","affiliation":[{"name":"Expert Involved in the Development of Recommendations Related to Drug Registrations, Paris, France"}]},{"given":"Beatriz","family":"Silva-Lima","sequence":"additional","affiliation":[{"name":"iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal"}]}],"member":"179","published-online":{"date-parts":[[2016,7,26]]},"reference":[{"key":"bibr1-1352458516650744","first-page":"1","author":"Mattke S","year":"2013","journal-title":"RAND"},{"key":"bibr2-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24009"},{"key":"bibr3-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2006.090365"},{"key":"bibr4-1352458516650744","unstructured":"The first Pan-European multiple sclerosis multi-stakeholder colloquium: Exploring opportunities and challenges for improving multiple sclerosis management. Agenda, http:\/\/2014.ms-colloquium.org\/programme (2014, accessed 3 December 2015)."},{"key":"bibr5-1352458516650744","unstructured":"The second Pan-European multiple sclerosis multi-stakeholder colloquium: Accelerating adoption of innovation for better care. Agenda, http:\/\/ms-colloquium.org\/programme (2015, accessed 3 December 2015)."},{"key":"bibr6-1352458516650744","unstructured":"The Pan-European multiple sclerosis multi-stakeholder colloquia. Calls to action, https:\/\/dl.dropboxusercontent.com\/u\/7697080\/MS%20Colloquium%202015\/Calll_to_action2015.pdf (2015, accessed 3 December 2015)."},{"key":"bibr7-1352458516650744","first-page":"1","author":"CPMP\/EWP\/561\/98","year":"2006","journal-title":"EMEA"},{"key":"bibr8-1352458516650744","first-page":"1","author":"EMA\/CHMP\/CNSWP\/257565\/2011","year":"2011","journal-title":"EMA"},{"key":"bibr9-1352458516650744","first-page":"1","author":"EMA\/CHMP\/771815\/2011","year":"2012","journal-title":"EMA"},{"key":"bibr10-1352458516650744","first-page":"1","author":"EMA\/576938\/2013","year":"2013","journal-title":"EMA"},{"key":"bibr11-1352458516650744","first-page":"1","author":"EMA\/CHMP\/771815\/2011","year":"2015","journal-title":"EMA"},{"key":"bibr12-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000306410.84794.4d"},{"key":"bibr13-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514546876"},{"key":"bibr14-1352458516650744","first-page":"150","volume":"66","author":"Lesaffre E","year":"2008","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"bibr15-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70059-5"},{"key":"bibr16-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/122.5.871"},{"key":"bibr17-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7094.1580"},{"key":"bibr18-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510374202"},{"key":"bibr19-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1191\/1352458506ms1289oa"},{"key":"bibr20-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12087"},{"key":"bibr21-1352458516650744","first-page":"1","author":"EMEA\/CHMP\/EWP\/139391\/2004","year":"2005","journal-title":"EMEA"},{"key":"bibr22-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.22102"},{"key":"bibr23-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000435551.90824.d0"},{"key":"bibr24-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awl208"},{"key":"bibr25-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306906"},{"key":"bibr26-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000036271.49066.06"},{"key":"bibr27-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13122566"},{"key":"bibr28-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516650739"},{"key":"bibr29-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1"},{"key":"bibr30-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31824e8ee7"},{"key":"bibr31-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.5"},{"key":"bibr32-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.345"},{"key":"bibr33-1352458516650744","first-page":"11","volume":"11","author":"Crommelin D","year":"2005","journal-title":"EJHP-S"},{"key":"bibr34-1352458516650744","first-page":"1","author":"CHMP\/437\/04","year":"2005","journal-title":"EMEA"},{"key":"bibr35-1352458516650744","first-page":"1","author":"EMEA\/CHMP\/BMWP\/42832\/2005","year":"2014","journal-title":"EMA"},{"key":"bibr36-1352458516650744","first-page":"1","author":"EMA\/CHMP\/BWP\/247713\/2012","year":"2014","journal-title":"EMA"},{"key":"bibr37-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2010.09.021"},{"key":"bibr38-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-013-9532-0"},{"key":"bibr39-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2012.08.009"},{"key":"bibr40-1352458516650744","unstructured":"The European commission implementing decision concerning, in the framework of Article 31 of Directive 2001\/83\/EC of the European Parliament and of the Council, the marketing authorisations of \u2018Iron containing intravenous medicinal products\u2019, medicinal products for human use, http:\/\/ec.europa.eu\/health\/documents\/community-register\/2013\/20130913126618\/dec_126618_en.pdf (2015, accessed 3 December 2015)."},{"key":"bibr41-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr024"},{"key":"bibr42-1352458516650744","first-page":"1","volume":"58","author":"Clark C","year":"2011","journal-title":"Hospital Pharmacy Europe"},{"key":"bibr43-1352458516650744","first-page":"1","author":"EMA\/CHMP\/SWP\/100094\/2011","year":"2011","journal-title":"EMA"},{"key":"bibr44-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.09.005"},{"key":"bibr45-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902802877"},{"key":"bibr46-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1517\/17425251003752715"},{"key":"bibr47-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1177\/1352458508098269"},{"key":"bibr48-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1177\/0192623311424169"},{"key":"bibr49-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2015.04.010"},{"key":"bibr50-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083757"},{"key":"bibr51-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1038\/srep10191"},{"key":"bibr52-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.1.284.284"},{"key":"bibr53-1352458516650744","unstructured":"FDA 2014-P-0933. Citizens petition requesting that FDA refrain from approving any abbreviated new drug application referencing Copaxone\u00ae until certain conditions are met, FDA 2014, pp. 1\u2013132, http:\/\/www.regulations.gov\/#!documentDetail;D=FDA-2014-P-0933-0001 (2014, accessed 3 December 2015)."},{"key":"bibr54-1352458516650744","unstructured":"FDA 2015-P1050. Citizens petition denial letter from CDER to Teva Pharmaceuticals, FDA 2015, pp. 1\u201343, http:\/\/www.noticeandcomment.com\/Citizen-Petition-Denial-Letter-From-CDER-to-Teva-Pharmaceuticals-fn-259296.aspx (2015, accessed 3 December 2015)."},{"key":"bibr55-1352458516650744","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2015.1042456"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458516650744","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458516650744","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458516650744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:07:21Z","timestamp":1740766041000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458516650744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,26]]},"references-count":55,"journal-issue":{"issue":"2_suppl","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1177\/1352458516650744"],"URL":"https:\/\/doi.org\/10.1177\/1352458516650744","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,26]]}}}